165 related articles for article (PubMed ID: 26958087)
1. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.
Vici P; Pizzuti L; Di Lauro L; Conti L; Mandoj C; Antenucci A; Digiesi G; Sergi D; Amodio A; Marchetti P; Sperati F; Valle M; Garofalo A; Vizza E; Corrado G; Vincenzoni C; Tomao F; Kayal R; Marsella A; Carosi M; Antoniani B; Giordano A; Maugeri-Saccà M; Barba M
J Cancer; 2016; 7(5):516-22. PubMed ID: 26958087
[TBL] [Abstract][Full Text] [Related]
2. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.
Pizzuti L; Sergi D; Mandoj C; Antoniani B; Sperati F; Chirico A; Di Lauro L; Valle M; Garofalo A; Vizza E; Corrado G; Tomao F; Rinaldi M; Carpano S; Maugeri-Saccà M; Conti L; Digiesi G; Marchetti P; De Maria R; Giordano A; Barba M; Carosi MA; Vici P
J Cell Physiol; 2018 Feb; 233(2):1396-1401. PubMed ID: 28542798
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
6. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
7. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.
Ratnavelu ND; Brown AP; Mallett S; Scholten RJ; Patel A; Founta C; Galaal K; Cross P; Naik R
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD010360. PubMed ID: 26930463
[TBL] [Abstract][Full Text] [Related]
9. Long-term results and prognostic factors in patients with epithelial ovarian cancer.
Brun JL; Feyler A; Chêne G; Saurel J; Brun G; Hocké C
Gynecol Oncol; 2000 Jul; 78(1):21-7. PubMed ID: 10873404
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.
Komura N; Mabuchi S; Yokoi E; Shimura K; Kawano M; Matsumoto Y; Kimura T
Int J Gynecol Cancer; 2019 Jul; 29(6):1057-1063. PubMed ID: 31203199
[TBL] [Abstract][Full Text] [Related]
12. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
Front Oncol; 2022; 12():970918. PubMed ID: 36237308
[TBL] [Abstract][Full Text] [Related]
13. Report of the committee on the classification and diagnostic criteria of diabetes mellitus.
; Seino Y; Nanjo K; Tajima N; Kadowaki T; Kashiwagi A; Araki E; Ito C; Inagaki N; Iwamoto Y; Kasuga M; Hanafusa T; Haneda M; Ueki K
J Diabetes Investig; 2010 Oct; 1(5):212-28. PubMed ID: 24843435
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
15. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
16. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes among young women with non-epithelial ovarian cancer: the YOC-Care study (Young Ovarian Cancer - Care).
Minig L; Gracia Segovia M; Arencibia O; Zorrero C; Marti L; García Pineda V; Cespedes J; Niguez I; Gil-Ibanez B; Diaz-Feijoo B; Fidalgo S; Valencia I; Alonso-Gutierrez T; Gonzalez L; Veiga-Fernandez A; Chacon E; Negredo I; Azcona Sutil L; Gorostidi M; Zapardiel I;
Int J Gynecol Cancer; 2023 Jun; 33(6):915-921. PubMed ID: 36796862
[TBL] [Abstract][Full Text] [Related]
19. Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.
Vici P; Crispo A; Giordano A; Di Lauro L; Sperati F; Terrenato I; Pizzuti L; Sergi D; Mottolese M; Botti C; Grimaldi M; Capasso I; D'Aiuto G; Di Bonito M; Di Paola F; Maugeri-Saccà M; Montella M; Barba M
J Cell Physiol; 2015 Aug; 230(8):1708-12. PubMed ID: 25510909
[TBL] [Abstract][Full Text] [Related]
20. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
